Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +51.68%
#2 TENDIES TENDIES +48.99%
#3 Pons Pons +46.31%
#4 PondCoin PondCoin +46.06%
#5 Magma Finance Magma Finance +33.33%
#6 StonkBroker StonkBroker +31.47%
#7 Purr Purr +29.09%
#8 Ocean Protocol Ocean Protocol +27.74%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +27.14%
#10 Starpower Starpower +26.90%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Settings
Language
ENGLISH
Currency
USD
Theme
General Biologicals Corporation General Biologicals Corporation

General Biologicals Corporation

4117
Rank in Stocks #29241
General Biologicals Corporation (GBC) is a company dedicated to the research,... General Biologicals Corporation (GBC) is a company dedicated to the research, development, production, and global commercialization of in-vitro diagnostic (IVD) solutions, operating extensively both within Taiwan and internationally. The company's core diagnostic offerings include advanced ELISA and chemiluminescence immunoassays, molecular and cellular diagnostic platforms, and rapid point-of-care testing (POCT) systems. Its diverse portfolio further encompasses COVID-19 related solutions, digital pathology, and contract development manufacturing organization (CDMO) services. Additionally, GBC provides essential blood screening services for detecting hepatitis and HIV, alongside crucial biomaterials such as antibody preparations and human plasma. Venturing beyond diagnostics, the company also markets a line of oral care products under its proprietary 'oh care' brand. These diagnostic systems are primarily utilized by clinics and laboratories. Founded in 1973, General Biologicals Corporation is headquartered in Hsinchu City, Taiwan.
Share Price
$0.31640033
Market Cap
$22.25M
Change (1 day)
-3.40%
Change (1 year)
-36.80%
Country
TW
Trade General Biologicals Corporation (4117)

Category

Healthcare
P/E ratio for General Biologicals Corporation (4117)
P/E ratio as of 2026 TTM: 0
According to General Biologicals Corporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for General Biologicals Corporation from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
STERIS plc STERIS plc
STERIS plc
STE.US
 28.45 -
IE
Shanghai United Imaging Healthcare Co., Ltd. Shanghai United Imaging Healthcare Co., Ltd.
Shanghai United Imaging Healthcare Co., Ltd.
688271.SS
 - -
CN
Ypsomed Holding AG Ypsomed Holding AG
Ypsomed Holding AG
YPSN.SW
 - -
CH
Medacta Group S.A. Medacta Group S.A.
Medacta Group S.A.
MOVE.SW
 - -
CH
Jafron Biomedical Co.,Ltd. Jafron Biomedical Co.,Ltd.
Jafron Biomedical Co.,Ltd.
300529.SZ
 - -
CN
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.